Global Innovative Platforms GIPL
OTC GIPL
$0.50 +0.00 (+0.00%)
At close: Oct 1, 2026 · 4:00 PM EDT

Global Innovative Platforms (GIPL) Return on Sales [ROS] (2025 - 2026)

Updated

Global Innovative Platforms' Return on Sales [ROS] was -476.55% in fiscal Q3 2026 (quarter ended Jun 30, 2026), down 334.40 percentage points from the prior quarter.

Analysis

Global Innovative Platforms (GIPL) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

On a trailing twelve-month basis, Global Innovative Platforms' Return on Sales [ROS] was -361.67% through Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 28.21%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 37.86%
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 32.97%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 20.57%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 34.95%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -133.21%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 28.37%
10 Global Innovative Platforms 24.88 Mn 24.27 Mn - -476.55%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -476.55%
Mar 31, 2026 -142.15%
Dec 31, 2025 -164.76%
API Access

Global Innovative Platforms Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=GIPL&period=max&api_key=YOUR_API_KEY